Avantax Planning Partners’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,652
| Closed | -$218K | – | 445 |
|
|
2024
Q4 | $218K | Hold |
1,652
| – | – | 0.01% | 400 |
|
|
2024
Q3 | $241K | Sell |
1,652
-10
| -0.6% | -$1.45K | 0.01% | 379 |
|
|
2024
Q2 | $228K | Hold |
1,662
| – | – | 0.01% | 414 |
|
|
2024
Q1 | $228K | Buy |
1,662
+29
| +2% | +$3.96K | 0.01% | 419 |
|
|
2023
Q4 | $222K | Sell |
1,633
-85
| -5% | -$10.4K | 0.01% | 343 |
|
|
2023
Q3 | $210K | Hold |
1,718
| – | – | 0.01% | 341 |
|
|
2023
Q2 | $218K | Hold |
1,718
| – | – | 0.01% | 343 |
|
|
2023
Q1 | $222K | Sell |
1,718
-550
| -24% | -$72K | 0.01% | 341 |
|
|
2022
Q4 | $298K | Hold |
2,268
| – | – | 0.01% | 301 |
|
|
2022
Q3 | $265K | Sell |
2,268
-41
| -2% | -$5.09K | 0.01% | 294 |
|
|
2022
Q2 | $272K | Buy |
2,309
+335
| +17% | +$39.8K | 0.01% | 285 |
|
|
2022
Q1 | $257K | Buy |
1,974
+283
| +17% | +$36.9K | 0.01% | 305 |
|
|
2021
Q4 | $258K | Buy |
1,691
+42
| +3% | +$6.5K | 0.01% | 298 |
|
|
2021
Q3 | $267K | Hold |
1,649
| – | – | 0.01% | 273 |
|
|
2021
Q2 | $270K | Buy |
1,649
+78
| +5% | +$12K | 0.01% | 270 |
|
|
2021
Q1 | $237K | Hold |
1,571
| – | – | 0.01% | 275 |
|
|
2020
Q4 | $238K | Hold |
1,571
| – | – | 0.01% | 253 |
|
|
2020
Q3 | $213K | Sell |
1,571
-1,423
| -48% | -$193K | 0.01% | 272 |
|
|
2020
Q2 | $409K | Buy |
2,994
+38
| +1% | +$4.84K | 0.02% | 193 |
|
|
2020
Q1 | $319K | Hold |
2,956
| – | – | 0.02% | 197 |
|
|
2019
Q4 | $356K | Sell |
2,956
-166
| -5% | -$18.5K | 0.02% | 212 |
|
|
2019
Q3 | $311K | Buy |
3,122
+29
| +0.9% | +$3.04K | 0.02% | 224 |
|
|
2019
Q2 | $333K | Buy |
3,093
+78
| +3% | +$8.3K | 0.02% | 221 |
|
|
2019
Q1 | $337K | Sell |
3,015
-645
| -18% | -$70.7K | 0.02% | 215 |
|
|
2018
Q4 | $353K | Hold |
3,660
| – | – | 0.03% | 174 |
|
|
2018
Q3 | $446K | Buy |
3,660
+1,682
| +85% | +$198K | 0.04% | 147 |
|
|
2018
Q2 | $217K | Sell |
1,978
-874
| -31% | -$93.5K | 0.02% | 222 |
|
|
2018
Q1 | $304K | Hold |
2,852
| – | – | 0.03% | 227 |
|
|
2017
Q4 | $305K | Sell |
2,852
-2,287
| -45% | -$244K | 0.03% | 226 |
|
|
2017
Q3 | $571K | Sell |
5,139
-396
| -7% | -$42.3K | 0.05% | 187 |
|
|
2017
Q2 | $572K | Sell |
5,535
-285
| -5% | -$28.1K | 0.05% | 178 |
|
|
2017
Q1 | $569K | Buy |
5,820
+1,260
| +28% | +$121K | 0.05% | 165 |
|
|
2016
Q4 | $403K | Buy |
+4,560
| New | +$415K | 0.04% | 191 |
|
Other funds holding IBB
MMEA
Avantax Planning Partners's IBB Position: Q1 2025 in Review
Avantax Planning Partners sold out of iShares Biotechnology ETF (IBB) in Q1 2025, closing a stake of 1,652 shares — an estimated $218K sold.
Avantax Planning Partners first reported a position in IBB in Q4 2016 and held it in 33 quarters. The position peaked at $572K in Q2 2017. 831 funds tracked by Wall St. Rank hold IBB as of Q1 2025.
- Avantax Planning Partners reported no remaining iShares Biotechnology ETF position as of Q1 2025 after selling out during the quarter.
- Avantax Planning Partners sold 1,652 iShares Biotechnology ETF shares in Q1 2025, an estimated $218K.
- Avantax Planning Partners first reported a position in iShares Biotechnology ETF in Q4 2016 and held it in 33 quarters.
- Avantax Planning Partners's iShares Biotechnology ETF position peaked at $572K in Q2 2017.
- 831 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2025.
Based on Avantax Planning Partners's 13F filing for Q1 2025, filed 29 Apr 2025.